INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jan 02, 2013 |
Director
Trans History: 547
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,000 | -- | 15,000 |
| Jan 02, 2013 |
Director
Trans History: 368
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,000 | -- | 15,000 |
| Jan 02, 2013 |
Director
Trans History: 320
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,000 | -- | 15,000 |
| Jan 02, 2013 |
Director
Trans History: 111
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,000 | -- | 15,000 |
| Sep 18, 2012 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 15,000 | $16.80 | 45,134 |
| Sep 18, 2012 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 15,000 | -- | -- |
| Aug 23, 2012 |
VP Regulatory Development and
Trans History: 288
|
VP Regulatory Development and | Form 4 | Open market or private sale of non-derivative or derivative security | 15,000 | $144.00 | 46,144 |
| Aug 07, 2012 |
Director
Trans History: 312
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 15,000 | $15.80 | 15,000 |
| Aug 07, 2012 |
Director
Trans History: 312
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 15,000 | $139.56 | -- |
| Aug 07, 2012 |
Director
Trans History: 312
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 15,000 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.